MX2009012957A - Metodo para tratar diabetes. - Google Patents

Metodo para tratar diabetes.

Info

Publication number
MX2009012957A
MX2009012957A MX2009012957A MX2009012957A MX2009012957A MX 2009012957 A MX2009012957 A MX 2009012957A MX 2009012957 A MX2009012957 A MX 2009012957A MX 2009012957 A MX2009012957 A MX 2009012957A MX 2009012957 A MX2009012957 A MX 2009012957A
Authority
MX
Mexico
Prior art keywords
diabetic
treating diabetes
hbaic
hyperglycemia
worsening
Prior art date
Application number
MX2009012957A
Other languages
English (en)
Spanish (es)
Inventor
Marcus Jerling
Andrew Wolff
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of MX2009012957A publication Critical patent/MX2009012957A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009012957A 2007-05-31 2007-05-31 Metodo para tratar diabetes. MX2009012957A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/070140 WO2008147417A1 (en) 2007-05-31 2007-05-31 Method of treating diabetes

Publications (1)

Publication Number Publication Date
MX2009012957A true MX2009012957A (es) 2010-03-03

Family

ID=38812044

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012957A MX2009012957A (es) 2007-05-31 2007-05-31 Metodo para tratar diabetes.

Country Status (11)

Country Link
EP (1) EP2152268A1 (ko)
JP (1) JP2010528112A (ko)
KR (1) KR20100038322A (ko)
CN (1) CN101678017A (ko)
AU (1) AU2007354300A1 (ko)
BR (1) BRPI0721741A2 (ko)
CA (1) CA2687381A1 (ko)
IL (1) IL202002A0 (ko)
MX (1) MX2009012957A (ko)
NO (1) NO20093592L (ko)
WO (1) WO2008147417A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
RU2320343C2 (ru) 2002-05-21 2008-03-27 Си Ви Терапьютикс, Инк. Способ лечения диабета
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
RU2691620C1 (ru) * 2018-11-26 2019-06-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ прогнозирования риска развития ишемической болезни сердца у пациентов с сахарным диабетом 2 типа в сочетании с субклиническим тиреотоксикозом
CN110812344A (zh) * 2019-12-17 2020-02-21 卓和药业集团有限公司 一种治疗糖尿病合并心绞痛的药物组合物及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
RU2320343C2 (ru) * 2002-05-21 2008-03-27 Си Ви Терапьютикс, Инк. Способ лечения диабета
CN101098682A (zh) * 2005-01-06 2008-01-02 Cv医药有限公司 包括雷诺嗪的缓释药物制剂

Also Published As

Publication number Publication date
BRPI0721741A2 (pt) 2013-02-13
IL202002A0 (en) 2010-06-16
CN101678017A (zh) 2010-03-24
AU2007354300A1 (en) 2008-12-04
NO20093592L (no) 2010-01-20
CA2687381A1 (en) 2008-12-04
KR20100038322A (ko) 2010-04-14
JP2010528112A (ja) 2010-08-19
EP2152268A1 (en) 2010-02-17
WO2008147417A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
PH12015502210A1 (en) Method for treating dependence
MX2010013876A (es) Agonistas de arilo grpr119 y sus usos .
WO2010049678A3 (en) Treatment of energy utilization diseases
BRPI0822955A2 (pt) método para operar um elevdor em um modo de emergência, e, elevador.
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
PH12016501607A1 (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
NZ592473A (en) Urinary biomarkers for predicting long-term dialysis
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
WO2007120936A3 (en) Use.of vildagliptin for the treatment of diabetes
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
WO2007124461A3 (en) Glp-1 compounds
ZA200901826B (en) Treating pain, diabetes, and lipid metabolism disorders
MX2022001797A (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico.
WO2008013863A3 (en) Generation of adipose tissue and adipocytes
WO2008084331A3 (en) Biomarkers for renal disorders
WO2009057119A3 (en) Glycemic control for reduction of cardiovascular disease risk in diabetic patients expressing haptoglobin 2-2
EP2203169A4 (en) GLYCEMIC INSPECTION, DIABETES TREATMENT, AND OTHER TREATMENTS WITH ACETYLCHOLINESTERASE INHIBITORS
MX2009012957A (es) Metodo para tratar diabetes.
WO2010037859A3 (en) Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2010124089A3 (en) Nepicastat for treating dependence
BR0311161A (pt) Método de tratamento de diabetes
WO2007053847A3 (en) Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis
PL2441462T3 (pl) Sposób leczenia cukrzycy typu I
WO2008131094A8 (en) Method for controlling glucose uptake and insulin sensitivity
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GILEAD SCIENCES, INC.

FA Abandonment or withdrawal